All companies
Insulet logo
HealthcarePODD

Insulet (PODD) Financial Forecast Calculator

Interactive 5-year forecast and DCF for Insulet. Adjust revenue growth, gross margin, capex intensity, WACC, and terminal growth - see revenue, free cash flow, and enterprise value update in real time. Seeded from Insulet’s most recent SEC filings.

Revenue FY30
$4.22B
from $1.70B
FCF FY30
-$649.1M
Margin -15.4%
Enterprise value
-$7.99B
-4.7× LTM revenue
Equity value
-$8.68B
Net debt $690.1M
Revenue & free cash flow - history and 5-year forecast
Line (area)
Bars
Historicals from SEC EDGAR (grey). Forecast years (color) update live as you move the sliders.

Assumptions

Revenue growth (annual)
20.0%
-10.0%baseline 20.0%40.0%
Gross margin
65.6%
5.0%baseline 65.6%90.0%
Capex % of revenue
12.1%
0.0%baseline 12.1%30.0%
WACC (discount rate)
9.00%
4.0%baseline 9.0%18.0%
Terminal growth
2.50%
0.0%baseline 2.5%5.0%

Need this as an Excel model?

Keep iterating on the Insulet forecast in Excel. The downloadable sample has every assumption you see here plus a fully integrated income statement, balance sheet, cash flow, and debt schedule - five years of SEC historicals and live formulas in a fully editable workbook.

income_statement.xlsx
Income statement, brown brand palette
income_statement.xlsx
Income statement, green brand palette
income_statement.xlsx
Income statement, red brand palette

Frequently asked

What does Insulet Corporation do?+

Insulet Corporation is an innovative medical device company that develops, manufactures, and sells the Omnipod system. This system provides continuous and tubeless automated insulin delivery for people with insulin-requiring diabetes.

How does Insulet Corporation generate revenue?+

Insulet operates a "razor and razorblade" business model, generating recurring revenue through the ongoing sale of disposable Omnipod pods via the pharmacy channel. Its U.S. Omnipod segment accounts for approximately 70% of total revenue, with International Omnipod contributing about 28%.

What are the key revenue growth assumptions in Insulet's financial model?+

The financial model for Insulet Corporation assumes a Revenue_Growth rate of 20% (0.2) for the forecast horizon. This reflects the company's high-growth trajectory, supported by factors like the expansion of its total addressable market.

What is the purpose of Insulet's equity valuation model?+

The model provides a comprehensive equity valuation and scenario analysis framework. Its purpose is to determine if Insulet's high-growth trajectory and operating margin expansion justify its premium market valuation amidst intensifying competition.

Can I download an Excel financial model for Insulet Corporation?+

Yes, an Excel financial model for Insulet Corporation (PODD) is available for download. This model offers a comprehensive framework for equity valuation and scenario analysis, forecasting through FY2030.

What is Insulet's competitive position in the automated insulin delivery market?+

Insulet holds a dominant competitive position as the global leader in tubeless insulin pumps, consistently ranking first in new customer starts. Key competitors include Tandem Diabetes Care, Medtronic, and Beta Bionics.

Have more financial modelling questions? Contact us

Go further

Build the financial model you need with Fina

Browse templates, examples, and downloadable Excel models for the analysis you are trying to build. If you can't find your model, ask Fina to build a model for your specific needs.

Start for free
Excel financial model spreadsheet preview showing Customer Rollforward
Fina interactive chat interface preview